QuidelOrtho Corp (QDEL)

Currency in USD
8.92
-0.65(-6.79%)
Closed·
8.920.00(0.00%)
·
Trading near 52-week Low
QDEL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.889.90
52 wk Range
8.8835.58
Key Statistics
Prev. Close
8.92
Open
9.61
Day's Range
8.88-9.9
52 wk Range
8.88-35.58
Volume
1.92M
Average Vol. (3m)
2.03M
1-Year Change
-58.1417%
Book Value / Share
26.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QDEL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.00
Upside
+68.16%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

QuidelOrtho Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 15.00
(+68.16% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Hold18.00+101.79%13.00MaintainJul 08, 2026
JPMorgan
Sell12.00+34.53%11.00MaintainJul 01, 2026
Jefferies
Hold12.50+40.13%-MaintainJun 29, 2026
UBS
Hold12.00+34.53%17.00MaintainMay 07, 2026
Jefferies
Hold12.50+40.13%35.00DowngradeMay 07, 2026

QuidelOrtho Corp SWOT Analysis


Analyst Perspectives
Learn about analyst price targets ranging from $50 to $61, reflecting varied views on QuidelOrtho's growth potential and market opportunities
Product Launch Hurdles
Delve into the challenges faced by QuidelOrtho in launching new products, particularly the delayed Savanna launch, and its impact on market position
Margin Expansion Drive
Explore QuidelOrtho's strategic focus on cost structure realignment and margin expansion, potentially leading to long-term earnings growth
Financial Resilience
QuidelOrtho's strong Q4 results and reaffirmed FY'25 guidance showcase the company's potential for growth and ability to meet future targets
Read full SWOT analysis

QuidelOrtho Corp Earnings Call Summary for Q3/2026

  • QuidelOrtho Q3 EPS of $0.31 beat estimates by 55%, but revenue of $618.9M missed forecasts by 1.5%, falling 12% YoY on constant-currency basis.
  • China revenue plunged 45% due to pricing reforms and destocking; point-of-care sales dropped 27% with respiratory testing down 39% year-over-year.
  • Company narrowed 2026 revenue guidance to $2.52B-$2.54B from $2.52B-$2.6B; expects China to fall to 4-5% of revenue in 2027 from 8% in 2026.
  • Announced restructuring program targeting $80M+ in annual savings for 2027; net leverage stands at 4.5x EBITDA with $2.8B net debt burden.
  • Shares fell 6.62% after-hours to $13.16 as investors focused on weak top-line growth, China headwinds, and cautious Q4 respiratory demand outlook.
Last Updated: 11/03/2026, 07:09 PM
Read Full Transcript
QuidelOrtho investor slides for Q3/2026
QuidelOrtho Q3 2026 slides
Last Update: Nov 04, 2026
See full investor slides

Earnings

Latest Release
Nov 03, 2026
EPS / Forecast
0.31 / 0.20
Revenue / Forecast
618.9M / 628.08M
EPS Revisions
Last 90 days

QDEL Income Statement

Compare QDEL to Peers and Sector

Metrics to compare
QDEL
Peers
Sector
Relationship
P/E Ratio
−1.7x−0.3x−0.2x
PEG Ratio
−0.02−0.390.00
Price / Book
0.3x2.5x2.6x
Price / LTM Sales
0.2x2.7x2.7x
Upside (Analyst Target)
68.2%8.6%72.2%
Fair Value Upside
Unlock6.5%12.4%Unlock

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
41.29M60.18%395.18M
Other Institutional Investors
48.95M39.82%468.48M
Public Companies & Retail Investors
0.000.00%0.00
Total
90.25M100.00%863.67M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.16.33%11,202,523107,208
Newtyn Management, LLC9.66%6,625,00063,401

People Also Watch

37.45
RHI
-8.39%
46.45
HRB
-3.29%
8.200
DNA
-2.84%
1.610
OPK
-4.73%
3.690
ATYR
-9.56%

FAQ

What Is the QuidelOrtho (QDEL) Stock Price Today?

The QuidelOrtho stock price today is 8.92 USD.

What Stock Exchange Does QuidelOrtho Trade On?

QuidelOrtho is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for QuidelOrtho?

The stock symbol for QuidelOrtho is "QDEL."

What Is the QuidelOrtho Market Cap?

As of today, QuidelOrtho market cap is 612.02M USD.

What Is QuidelOrtho's Earnings Per Share (TTM)?

The QuidelOrtho EPS (TTM) is -5.40.

When Is the Next QuidelOrtho Earnings Date?

QuidelOrtho will release its next earnings report on Feb 17, 2027.

From a Technical Analysis Perspective, Is QDEL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has QuidelOrtho Stock Split?

QuidelOrtho has split 0 times.

How Many Employees Does QuidelOrtho Have?

QuidelOrtho has 6500 employees.

What is the current trading status of QuidelOrtho (QDEL)?

As of Nov 20, 2026, QuidelOrtho (QDEL) is trading at a price of 8.92 USD, with a previous close of 8.92 USD. The stock has fluctuated within a day range of 8.88 USD to 9.90 USD, while its 52-week range spans from 8.88 USD to 35.58 USD.

What Is QuidelOrtho (QDEL) Price Target According to Analysts?

The average 12-month price target for QuidelOrtho is 15.00 USD, with a high estimate of 20 USD and a low estimate of 12 USD. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +68.16% Upside potential.

What Is the QDEL Premarket Price?

QDEL's last pre-market stock price is 10.50 USD. The pre-market share volume is 200.00, and the stock has decreased by 0.93, or 9.72%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.